Lyell Immunopharma (LYEL) Stock Statistics & Valuation Metrics

Lyell Immunopharma has a market cap or net worth of $136.21M. The enterprise value is -$28.27M.

Lyell Immunopharma has 295,337,550 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lyell Immunopharma’s return on equity (ROE) is -0.90 and return on invested capital (ROIC) is -0.76%.

The current PE Ratio of Lyell Immunopharma is -0.49. Lyell Immunopharma’s PEG ratio is -0.01.

In the last 12 months, Lyell Immunopharma had revenue of 61.00K and earned -342.99M in profits. Earnings per share was -1.31.

In the last 12 months, operating cash flow was -162.39M and capital expenditures -464.00K, giving a free cash flow of -162.86M billion.

Lyell Immunopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Lyell Immunopharma upcoming earnings date is May 13, 2025, TBA Not Confirmed.

Lyell Immunopharma as a current ratio of 7.06, with Debt / Equity ratio of 15.40%

In the past 12 months, Lyell Immunopharma has paid 0.00 in taxes.

Lyell Immunopharma EV to EBITDA ratio is -34.07, with an EV/FCF ratio of -0.69.

Lyell Immunopharma has $370.53M in cash and marketable securities with $58.97M in debt, giving a net cash position of -$311.56M billion.

Gross margin is -16170.49%, with operating margin of -5424.59%, and net profit margin of -562285.25%.

The average price target for Lyell Immunopharma is $1.00, which is 11.43% higher than the current price. The consensus rating is Moderate Sell